HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX) and maintained a price target of $6. This endorsement reflects the firm's confidence in the company's prospects.